Abstract
Background and Aims: Inadequate bowel preparation and high cancellation rates hinder the effectiveness of colonoscopy screening programs. We aimed to evaluate the impact of a novel, personalized video messaging platform on bowel preparation quality and colonoscopy adherence. Methods: We conducted a before-after intervention study at a large urban academic medical center, comparing outcomes between a historical control group (April-September 2022) and an intervention group receiving personalized video messages (July-November 2023). Primary outcomes were inadequate bowel preparation and colonoscopy cancellation/rescheduling rates. Propensity score matching and multivariable logistic regression were used to adjust for potential confounders. Results: Among 1,647 patients who underwent colonoscopy, inadequate bowel preparation occurred in 12.0% of the intervention group versus 20.0% of the historical control group in the propensity score matched analysis (p=0.041). In the larger cohort of 2,802 scheduled patients, the propensity score matched analysis showed a trend toward a 31% reduction in odds of cancellation or rescheduling associated with the educational video, although this did not reach statistical significance (OR 0.69, 95% CI 0.47-1.01, p=0.056). For the logistical regression model, the video was associated with a 42% reduction in odds of cancellation or rescheduling (adjusted OR 0.58, 95% CI 0.44-0.77, p<0.001). Conclusions: Implementation of a personalized video messaging platform was associated with significant improvements in bowel preparation quality and substantial reductions in colonoscopy cancellations/rescheduling. This easily scalable, low-cost intervention has the potential to enhance the efficiency and effectiveness of colonoscopy screening programs.
Competing Interest Statement
These authors disclose the following: Dr Shitij Arora has received grant support from Amazon Web Services Health Equity Initiative. He is a member of the scientific advisory board at HealthiPeople. Rohit Maheshwari is the CEO and founder of HealthiPeople. The remaining authors disclose no conflicts.
Funding Statement
These authors disclose the following: Dr Shitij Arora has received grant support from Amazon Web Services Health Equity Initiative.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board (IRD) of Montefiore Einstein gave ethical approval for this work. IRB #: 2022-14321
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.